Cure My Disease

Don't miss your cure!

 Log in / Sign up

New gastritis drug candidate tested in three formulations to find the best acid controller

NCT ID NCT07717775

Disease control Sponsor: Addpharma Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 21, 2026 · Last updated Jul 28, 2026 · Updated 3 times

Summary

This trial tests three different tablet versions of an experimental drug called AD-234 in healthy adults aged 19 to 50. The goal is to see which formulation best controls stomach acid levels over 24 hours after a week of daily dosing. Researchers will also compare how the body absorbs each version and check for side effects. The results will help decide which formulation to study further in people with gastritis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an experimental drug for gastritis, tested in three different formulations called AD-234, AD-2341, and AD-2342
What this could lead to
If successful, this could identify the best formulation of AD-234 for controlling stomach acid, potentially leading to a new treatment option for gastritis.
What could go wrong
This is an early-phase trial in only 30 healthy volunteers, not people with gastritis. The drug may not work as well in actual patients or may have side effects not seen here.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 to 50 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy adult volunteers aged 19 to 50 years, inclusive, at the time of screening * Body weight between 50.0 kg and 90.0 kg, inclusive, and body mass index (BMI) between 18.5 kg/m\^2 and 29.9 kg/m\^2, inclusive, at the time of screening (BMI = weight \[kg\] / height \[m\]\^2) * For female participants: not pregnant, not breastfeeding, or surgically sterile (e.g., bilateral tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy) Exclusion Criteria: * Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration Other exclusions applied

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastritis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastritis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Seoul National University Hospital, Seoul,

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.